image: Journal of Child and Adolescent Psychopharmacology is dedicated to child and adolescent psychiatry and behavioral pediatrics, covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology. view more
Credit: Mary Ann Liebert Inc., publishers
New Rochelle, NY, February 21, 2019--A new short-term pilot study in children and teens 6-17 years old with attention-deficit hyperactivity disorder (ADHD) has shown saffron to be as effective at controlling symptoms as methylphenidate, the commonly prescribed drug Ritalin. Saffron may be a promising herbal alternative for treating ADHD, particularly for the 30% of patients who do not respond to or cannot tolerate stimulants like methylphenidate, as reported in an article published in the Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the Journal of Child and Adolescent Psychopharmacology website through March 21, 2019.
The article entitled "Crocus sativus L. Versus Methylphenidate in Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study" was coauthored by Sara Baziar, MD, Ali Aqamolaei, MD and colleagues from Tehran University of Medical Sciences, Iran. The researchers note that saffron also has anti-depressant and memory-enhancing properties. They compared the effects of Crocus sativus L. to methylphenidate in 54 patients over a 6-week period and showed no significant difference in effectiveness as well as similar frequency of adverse effects.
"This is a very interesting study and an intriguing finding. It is worthy of replication and further study to understand the mechanism of action," says Harold S. Koplewicz, MD, Editor-in-Chief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York.
###
About the Journal
Journal of Child and Adolescent Psychopharmacology is an authoritative peer-reviewed journal published bimonthly in print and online. The Journal is dedicated to child and adolescent psychiatry and behavioral pediatrics, covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology. Complete tables of content and a sample issue may be viewed on the Journal of Child and Adolescent Psychopharmacology website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cyberpsychology, Behavior, and Social Networking, Games for Health Journal, and Violence and Gender. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Journal
Journal of Child and Adolescent Psychopharmacology